SiRNA structures for high activity and reduced off target

Patent metadata

Field	Value
Publication number	US-11390871-B2
Application number	US-201916451757-A
Country	US
Kind code	B2
Filing date	Jun 25, 2019
Priority date	Dec 13, 2015
Publication date	Jul 19, 2022
Grant date	Jul 19, 2022

Abstract

This invention provides compounds, compositions and methods for modulating the expression of target genes using RNA interference. RNAi structures and molecules of this invention can be used for modulating or silencing the expression of genes, with high levels of RNAi activity and reduced off target actions. Advantageous structures include siRNAs targeted to any gene having one or more 2′-deoxy nucleotides located in the seed region. The RNA interference molecules can be used in methods for preventing or treating diseases.

First claim

What is claimed is:

1. A siRNA or RNAi nucleic acid molecule, wherein:
a) the molecule has a polynucleotide sense strand and a polynucleotide antisense strand;
b) each strand of the molecule is from 15 to 30 nucleotides in length;
c) at least a portion of the sense strand is complementary to at least a portion of the antisense strand, and the molecule has a duplex region of from 15 to 30 nucleotides in length, wherein three of the six nucleotides in the duplex region at positions 3 to 8 from the 5′ end of the antisense strand are deoxynucleotides, and all the remaining three nucleotides of the six nucleotides in the duplex region at positions 3 to 8 from the 5′ end of the antisense strand are not deoxynucleotides; and
d) wherein the molecule is active for modulating expression of an mRNA.

2. The siRNA or RNAi nucleic acid molecule of claim 1 , wherein the antisense strand has deoxynucleotides in a plurality of positions, the plurality of positions being one of the following:
each of positions 4, 6 and 8, from the 5′ end of the antisense strand;
each of positions 3, 5 and 7, from the 5′ end of the antisense strand; and
each of positions 1, 3, 5 and 7, from the 5′ end of the antisense strand.

3. The siRNA or RNAi molecule of claim 1 , further comprising a contiguous region of from 15 to 30 nucleotides of the antisense strand which is complementary to a sequence of the mRNA.

4. The siRNA or RNAi molecule of claim 1 , wherein the molecule is active for inhibiting expression of a gene selected from the group consisting of a protein coding gene, a proto-oncogene, an oncogene, a tumor suppressor gene, and a cell signaling gene.

5. The siRNA or RNAi molecule of claim 1 , wherein the mRNA is a human mRNA.

6. The siRNA or RNAi molecule of claim 1 , wherein the mRNA is a human mRNA expressing any member or sub-member of the human family of proteins comprising SRY, beta-globin, RAS, cytosolic GST, mitochondrial GST, MAPEG GST, GST-π, p16, p21, p53, serum albumin, Type VII collagen, Complement C3, Apolipoprotein B, phenylalanine hydroxylase, Factor VIII, Huntingtin, RB1 retinoblastoma protein, CFTR, Titin, Utrophin, and Dystrophin.

7. The siRNA or RNAi molecule of claim 1 , wherein the molecule has an IC50 for knockdown of the mRNA of less than 100 pM.

8. The siRNA or RNAi molecule of claim 1 , wherein the molecule has an IC50 for knockdown of the mRNA of less than 50 pM.

9. The siRNA or RNAi molecule of claim 1 , wherein the molecule has an IC50 for knockdown of the mRNA of less than 10 pM.

10. The siRNA or RNAi molecule of claim 1 , wherein a single administration of the molecule inhibits the mRNA by at least 25% in vivo.

11. The siRNA or RNAi molecule of claim 1 , wherein each strand of the molecule is from 18 to 22 nucleotides in length.

12. The siRNA or RNAi molecule of claim 1 , wherein the duplex region is 19 nucleotides in length.

13. The siRNA or RNAi molecule of claim 1 , wherein the polynucleotide sense strand and the polynucleotide antisense strand are connected as a single strand, and form a duplex region connected at one end by a loop.

14. The siRNA or RNAi molecule of claim 1 , wherein the molecule has a blunt end.

15. The siRNA or RNAi molecule of claim 1 , wherein the molecule has one or more 3′ overhangs.

16. The siRNA or RNAi molecule of claim 1 , wherein one or more of the nucleotides in the duplex region is modified or chemically-modified.

17. The siRNA or RNAi molecule of claim 16 , wherein the modified or chemically-modified nucleotides are 2′O-alkyl substituted nucleotides, 2′-deoxy-2′-fluoro substituted nucleotides, phosphorothioate nucleotides, locked nucleotides, or any combination thereof.

18. A pharmaceutical composition comprising the siRNA or RNAi molecule of claim 1 and a pharmaceutically acceptable carrier.

19. The pharmaceutical composition of claim 18 , wherein the carrier comprises a lipid molecule or liposome.

20. A vector or isolated cell comprising the siRNA or RNAi molecule of claim 1 .

21. A method for treating or ameliorating a disease in a subject in need by gene silencing, the method comprising administering the pharmaceutical composition of claim 18 to the subject.

22. The method of claim 21 , wherein the disease is malignant tumor, cancer, sarcoma, or carcinoma.

Assignees

• Nitto Denko Corp

Inventors

• Minomi Kenjirou
• Harborth Jens
• Cina Cima
• Ying Wenbin
• Zheng Jane
• Vaish Narendra

Classifications

• C12N15/111

  General methods applicable to biologically active non-coding nucleic acids · CPC title

• C12Y205/01018

  Glutathione transferase (2.5.1.18) · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• C12N2310/321

  2'-O-R Modification · CPC title

• C12N2310/343

  having patterns, e.g. ==--==--==-- · CPC title